Skip to main content

Table 1 Baseline characteristics of patients

From: Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders

Characteristics All patients (N = 147) Patients who were evaluated for SVR (N = 132) Patients with treatment discontinuation or loss to follow-up (N = 15)
Age*, mean ± SD (years) 41.1 ± 11.6 41.2 ± 11.9 40.1 ± 8.7
Gender, n (%)    
 Male 139 (94.6%) 126 (95.5%) 13 (86.7%)
 Female 8 (5.4%) 6 (4.5%) 2 (13.3%)
Hereditary bleeding disorder types, n (%)    
 Hemophilia A 113 (76.9%) 106 (80.3%) 7 (46.7%)
 Hemophilia B 19 (12.9%) 14 (10.6%) 5 (33.3%)
 VWD 8 (5.4%) 6 (4.5%) 2 (13.3%)
 Glanzmann 1 (0.7%) 1 (0.8%) 0 (0%)
 Other disorders 6 (4.1%) 5 (3.8%) 1 (6.7%)
HIV co-infection, n (%) 6 (4.1%) 5 (3.8%) 1 (6.7%)
HBV co-infection, n (%) 0 (0%) 0 (0%) 0 (0%)
Platelet count**, mean ± SD (109/L) 200.0 ± 59.3 197.8 ± 59.4 219.8 ± 56.6
Hemoglobin**, Median (IQR) (g/dL) 15.7 (14.3–16.9) 15.7 (14.4–16.9) 15.3 (11.1–17.3)
AST**, Median (IQR) (IU/L) 38 (27–55) 38 (27–55) 38 (32–76)
ALT**, Median (IQR) (IU/L) 42 (27–70) 42 (30–70) 46 (19–72.5)
HCV RNA*, mean ± SD (log10 IU/mL) 6.0 ± 0.8 5.9 ± 0.8 6.2 ± 0.5
Liver stiffness measurement (Metavir score)*, n (%)    
 F0–F2 75 (54%) 66 (52.8%) 9 (64.3%)
 F2–F4 33 (23.7%) 31 (24.8%) 2 (14.3%)
 F4 31 (22.3%) 28 (22.4%) 3 (21.4%)
Cirrhosis, n (%)    
 Non-cirrhotic 110 (74.8%) 99 (75%) 11 (73.3%)
 Compensated cirrhosis 32 (21.8%) 29 (22.0%) 3 (20%)
 Decompensated cirrhosis 5 (3.4%) 4 (3.0%) 1 (6.7%)
HCV genotype*, n (%)    
 1 98 (68.1%) 89 (68.5%) 9 (64.3%)
 2 2 (1.4%) 2 (1.5%) 0 (0%)
 3 30 (20.8%) 27 (20.8%) 3 (21.4%)
 4 4 (2.8%) 4 (3.1%) 0 (0%)
 Mix 10 (6.9%) 8 (6.1%) 2 (14.3%)
Previous treatment experience, n (%)    
 Treatment naïve 68 (46.3%) 61 (46.2%) 7 (46.7%)
 Interferon-experienced 79 (53.7%) 71 (53.8%) 8 (53.3%)
 DAA-experienced 0 (0%) 0 (0%) 0 (0%)
  1. SD standard deviation, IQR interquartile range, DAA direct-acting antiviral agent, VWD Von Willebrand disease, SVR sustained virologic response, n number, HIV human immunodeficiency virus, HBV hepatitis B virus, ALT alanine aminotransferase, AST aspartate aminotransferase
  2. *Data were missed in less than 10% of patients
  3. **Data were missed in more than 10% of patients